Home

ABOUT

Editorial

PRESS RELEASES

MEDICAL DEVICE NEWS MAGAZINE

A DIGITAL PUBLICATION FOR THE PRACTICING MEDICAL SPECIALIST, INDUSTRY EXECUTIVE AND INVESTOR

SUBSCRIBE

Market Reports

FDA

Executives

Funding

Non Profits

Hospitals

Acquisitions

Health

Biotechnology News Magazine

HomeCancer Detection

Cancer Detection

Martell Diagnostic Laboratories Announces HERTEST: Groundbreaking Way to Detect Effectiveness of Breast Cancer RX Globally

HERTEST is a blood test that looks for a protein called human epidermal growth factor receptor (HER2), which is shed into the blood stream of patients with growing breast cancer tumors.

EarlyCDT Lung Partnership Contract Signed Reports Oncimmune Holdings

With one of the world’s largest pharmaceutical companies, Oncimmune will further evaluate EarlyCDT Lung for the detection of lung cancer in at-risk patients. The initial phase of the collaboration will assess the utility of Early CDT Lung test at detecting incident lung cancer cases in a screening setting.

Thrive Earlier Detection Announces Groundbreaking Clinical Data from the First Ever Interventional Study of a Blood-Based Test to Screen and Identify Multiple Types of Cancer

The study was conducted by Johns Hopkins University and Geisinger and enrolled more than 10,000 women with no prior history of cancer.

New Full-Body Scan Detects Up To 11 Cancers In Men and 13 In Women

"We should all check our bodies for cancer as part of our routine health regimen. To make that possible, we're aiming to combine a  better patient experience with the most advanced medical imaging technology and the latest developments in artificial intelligence," said Emi Gal, CEO & co-founder of Ezra. "Our goal is to improve the speed, accuracy and affordability of cancer screening, and I'm thrilled to be announcing our full-body MRI-based cancer screening program." 

Significant Progress with Multi Cancer Early Detection Test

GRAIL, Inc., announced that its multi cancer early detection test has been granted Breakthrough Device designation from the U.S. Food and Drug Administration (FDA). The investigational blood test is in development for the early detection of multiple cancer types in individuals aged 50 or older.

Asuragen NGS System for Streamlined Detection of RNA Lung Cancer Variants Demonstrates Superior Performance in Multisite Evaluation

1/29/19: The peer-reviewed article, titled “Design, Optimization, and Multisite Evaluation of a Targeted Next-Generation Sequencing Assay System for Chimeric RNAs from Gene Fusions and Exon-Skipping Events in Non–Small Cell Lung Cancer,” also describes the design and development of the assay system. This system includes controls, pre-analytical sample QC, targeted RNA-based enrichment, library clean-up and pooling, and companion bioinformatics software that analyzes the corresponding next-generation sequencing (NGS) data.

By using this website you agree to accept Medical Device News Magazine Privacy Policy